Thank you very much for your interest in the EVEREST Pre-Congress Symposium. The symposium will take place on 13th September 2023. Participation in the EVEREST Pre-Congress Symposium is included for congress participants but requires registration. Please note, that the EVEREST Pre-Congress Symposium will only take place in-person and is not broadcasted digitally.
Pediatric low-grade brain tumors account for the most common brain tumors in children. Although most of the children survive this tumor type it does come with costs on the quality of life due life-long struggles and treatment for them and their families. For many years low-grade gliomas were largely understudied and have only recently gained enormous insights into their genetic drivers due to incredible advances in technology and molecular diagnostic. In fact, the new molecular classifications helped improve the understanding of the disease resulting in a more precise stratification, which found a way in the newest WHO tumor classification.
The EVEREST Pre-Congress Symposium On low-grade glial and glioneuronal tumors will touch the latest research and cutting-edge technological advances from Omics, Diagnostics and Microenvironment interactions to the biology of MAPK signaling and preclinical models.
Invited and confirmed keynote speaker are:
Pratiti (Mimi) Bandopadhayhay and Keith Ligon
(Dana-Faber Cancer Center, Broad Institute, Boston Children’s Hospital and Harvard Medical School, Boston, USA)
Wednesday - 13th September 2023
| 9:00 - 9:10 | Introduction - David Jones and Mimi Bandopadhayay | |||
| 9:10 - 10:30 | Pediatric LGGNTs – Omics, Diagnostics & Microenvironment interactions | |||
9:10 - 9:50 | Keynote: Mimi Bandopadhayay (Boston, USA) FGFR alterations in pLGGs' | |||
9:50 -10:10 |
| Ashwyn Perera (Heidelberg, Germany) | ||
10:10 - 10:30 |
| Arend Koch (Berlin, Germany) | ||
| 10:30 - 10:50 | Coffee Break | |||
| 10:50 - 12:10 | Pediatric LGGNTs – Biology of MAPK Signaling & Pre-clinical Models | |||
10:50 - 11:30 | Keynote: Keith Ligon (Boston, USA) Beyond BRAF: insights from preclinical models of other pLGG drivers | |||
11:30 - 11:50 | Daniela Kocher (Heidelberg, Germany) Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPK inhibitor withdrawal in pediatric low-grade glioma | |||
11:50 - 12:10 | Denise Sheer (London, UK) MAPK and More: Signalling networks in paediatric low-grade glioma | |||
| From 12:10 | Lunch snacks and departure or | |||
| 13:00 | Start of the 20th International Congress of Neuropathology (ICN) |